Form 4: CRISPR Therapeutics Director Receives Stock Option Grant

Director Simeon George was granted 13,000 stock options in CRISPR Therapeutics AG as part of standard equity compensation.

Summary

• Director Simeon George received a grant of 13,000 stock options for CRISPR Therapeutics AG (CRSP).
• The options have an exercise price of $51.84 per share.
• The grant date for these options is June 5, 2026.
• The options are set to expire on June 5, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment as it reflects standard corporate governance rather than a change in company strategy or financial performance.

Positives

• The grant aligns the director's interests with long-term shareholder value through equity-based compensation.

Negatives

• The issuance of new stock options results in potential future dilution for existing shareholders.

Risks

• The value of the options is dependent on the future market performance of CRSP common shares.
• Vesting is subject to continued service to the company.

Future Outlook

The options vest in 12 equal monthly installments, with the final installment vesting by the earlier of the one-year anniversary of the grant or the 2027 Annual Meeting, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise, particularly for companies focused on gene editing and long-term R&D cycles.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard corporate governance practices for mid-cap biotechnology firms.
• The use of monthly vesting over one year is a common retention mechanism for board members in the life sciences industry.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of the first installment of options on June 30, 2026.

Key Dates

Keywords

CRISPR Therapeutics, CRSP, Stock Options, Director Compensation, Insider Transaction, Biotech